Connect your AI

Anika Therapeutics ANIK Inventories

Inventories at other companies

StrykerSYK

$5.42B+6.2%

VericelVCEL

$18.35M+7.3%

Zimmer Biomet HoldingsZBH

$2.25B+0.1%

Pacira BioSciences, Inc.PCRX

$150.37M+12.4%

BioventusBVS

$83.19M-11.5%

Xtant Medical HoldingsXTNT

$31.88M-17.9%

Other financials

Income statement

Revenue$29.6M+13.2%

Net income-$5.1M-3.8%

Balance sheet

Cash & equivalents$41.0M-23.1%

Total debt$25.7M+1.2%

Total equity$133.9M-9.8%

Total assets$179.4M-5.9%

Cash flow

Operating cash flow-$4.8M-3,628%

CapEx$1.4M-49.3%

Free cash flow-$6.3M-112%

Valuation

Market cap$204.37M+31.6%

Enterprise value$189.09M+48.7%

P/S1.8×+0.1×

Profitability

Net margin-9.8%-4.4pp

FCF margin0.9%—

Returns & leverage

Return on equity-8%-3.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.3×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InventoryNet.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Anika Therapeutics's inventories?: Anika Therapeutics (ANIK) reported inventories of $22.84M in Q1 2026.
How has Anika Therapeutics's inventories changed year-over-year?: Anika Therapeutics's inventories increased by 7.0% year-over-year, from $21.34M to $22.84M.
What is the long-term trend for Anika Therapeutics's inventories?: Over 5 years (2020 to 2025), Anika Therapeutics's inventories has grown at a -16.5% compound annual growth rate (CAGR), from $46.21M to $18.79M.
What does inventories mean?: Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.